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ABSTRACT
We have previously shown that hedamycin, a
GC-rich DNA-binding antitumor agent, downregu-
lates survivin transcription (Wu et al. (2005)
Molecular mechanism of inhibition of survivin
transcription by the GC-rich sequence selective
DNA-binding antitumor agent, hedamycin: evidence
of survivin downregulation associated with drug
sensitivity. J. Biol. Chem., 280, 9745–9751). Here, we
report that treatment of cancer cells with
Hoechst33342, an AT-rich DNA-binding ligand,
upregulated survivin protein, mRNA and promoter
activity. Functional analysis of survivin promoter-
luciferase constructs followed by in vivo footprint-
ing experiments identified a 28-bp AT-rich DNA
element ( 908 to  881, designated as H369W) that
mediates a major effect of Hoechst33342 on the
upregulation of survivin promoter activity.
Electrophoresis mobility shift assay (EMSA) experi-
ments showed that Hoechst33342 binds to H369W
and abrogates H369W–protein interactions.
Intriguingly, there is a highly conserved DNA-
binding motif for growth factor independence 1
(Gfi-1), a transcriptional repressor protein, in the
H369W DNA element. Accordingly, EMSA experi-
ments demonstrated that either the cold canonical
Gfi-1-binding DNA oligonucleotide or the cold
H369W specifically competes with H369W–protein
complexes. Consistently, anti-Gfi-1 antibody is
able to supershift the H369W–protein complex
on the EMSA gel. Lastly, our data reveal that
upregulation of survivin by Hoechst33342 is
involved in cancer drug resistance. We propose
that hindrance of H369W–Gfi-1 interactions in
the survivin promoter, initiated by Hoechst33342,
contributes to upregulation of survivin transcription,
and as a consequence, hampers Hoechst33342’s
cytotoxicity.
INTRODUCTION
Survivin, a novel member of the inhibitor of apoptosis
(IAP) family proteins (1–3), is known to be involved in the
regulation of apoptosis and the control of cell division
(4–6). Survivin expression in cancer cells is associated with
tumorigenesis (7), cancer progression, poor prognosis,
shortened patient survival and drug/radiation resistance
(4,6). We previously reported that hedamycin, a GC-rich
sequence-selective DNA-binding antitumor agent, tran-
scriptionally downregulates the expression of survivin (8).
We have shown that the downregulation of survivin
transcription by hedamycin is, at least in part, due to the
binding of hedamycin to a 21-bp GC-rich DNA motif in
the survivin promoter, which abrogates the binding of Sp-
1 or Sp1-like transcription factors (8). We have further
shown that downregulation of survivin expression by
hedamycin is a contributor to hedamycin-induced cancer
cell death (8). In the present study, we report that an
AT-rich sequence-selective DNA-binding ligand,
Hoechst33342, upregulates survivin transcription and, in
so doing, plays a role in Hoechst33342 resistance.
Mechanistically, we discovered that upregulation of
survivin transcription by Hoechst33342 is at least partially
due to Hoechst33342 binding to and abolishment of the
DNA–protein interactions in a 28-bp AT-rich DNA
element, designated as H369W, in the survivin enhancer
region. This includes, but may not be limited to,
disturbance of the interaction between the transcription
repressor protein Gﬁ-1 or Gﬁ1-like proteins and the
H369W DNA motif. We further showed that
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MATERIALS AND METHODS
Cell cultureand reagents
HeLa cervical epithelial carcinoma cells were maintained
in Dulbecco’s modiﬁed Eagle’s medium (DMEM), while
HCT116 colon cancer cells and U937 histiocytic lym-
phoma cells were maintained in RPMI1640, supplemented
with 10% fetal bovine serum (Mediatech Cellgro,
Herndon, VA, USA) and 100 units/ml of penicillin/
100mg/ml of streptomycin (Invitrogen, Carlsbad, CA,
USA) in a humid atmosphere incubator with 5% CO2 at
378C. Cells were routinely subcultured twice weekly. The
anti-survivin antibody (FL-142) and anti-Gﬁ-1 antibody
(N-20) were purchased from Santa Cruz (Santa Cruz, CA,
USA). Hoechst33342, propidium iodide (PI), dimethyl
sulfate (DMS), piperidine, 40,6-diamidino-2-phenylindole
(DAPI), Distamycin, anti-actin antibody and goat perox-
idase-conjugated anti-rabbit IgG antibody were purchased
from Sigma (St. Louis, MO, USA). Dual-Luciferase
Reporter Assay System and T4 DNA ligase were
purchased from Promega (Madison, WI, USA). Vent
DNA polymerase and restriction enzymes were from New
England Biolabs (Beverly, MA, USA). Lipofectamine
TM
2000 reagents were purchased from Invitrogen (Carlsbad,
CA, USA). Fugene HD transfection reagents were
purchased form Roche (Indianapolis, IN, USA).
Ligandtreatment and western blot
Cells were treated with Hoechst33342 using complete
medium containing 10% fetal bovine serum (FBS) in all
experiments. Western blot analysis of survivin and actin
expression was performed as previously described (9).
Survivin and actin signals were detected using an HRPL
kit (National Diagnostics/LPS, Rochester, NY, USA) and
visualized by autoradiography after various times
(20–120s) of exposure.
Total RNA isolationand northernblot
Total RNAs were isolated from cells with or
without DNA-binding drug treatments. The mRNAs for
survivin and glyceraldehydes 3-phosphate dehydrogenase
(GAPDH) were analyzed by northern blot as we
previously described (10).
Quantitative real-time PCR (real-time QPCR)
Total RNA was extracted from cells using the Absolutely
RNA Miniprep kit (Stratagene, La Jolla, CA, USA).
Total RNA (0.5mg) was converted to cDNA using the
StrataScript QPCR cDNA Synthesis Kit (Stratagene).
Quantitative real-time PCR was performed using cDNA
converted from 25ng total RNA, and analyzed on the
Applied Biosystems 7300 Real-Time PCR System to
determine mRNA levels of survivin, Gﬁ-1 and actin
(internal control). The iTaq SYBR Green Supermix with
ROX (Bio-Rad, Hercules, CA, USA) was used for all
real-time PCR reactions. The primers used in this study
were: hSv50P1 (GAGGCTGGCTTCATCCACTG) and
hSv30P2 (GCACTTTCTTCGCAGTTTCCTC) for the
survivin PCR product (277bp); Gﬁ1-f4 (AGCCGTGC
ACTCGCAGGAAC) and Gﬁ1-r4 (GTGAGGCTTCTC
ACCAGTGT) for the Gﬁ-1 PCR product (196bp); and
Actin-f (ATGGGTCAGAAGGATTCCTAT) and Actin-
r (AAGGTCTCAAACATGATCTGGG) for the b-actin
PCR product (242bp). The real-time QPCR condition is
958C for 3min as a pre-denature step, followed by 40 PCR
cycles at 958C for 15s and 608C for 45s. Data presented in
this study was collected at 608C applying a threshold of
0.002 and normalized to actin using the default RQ ddCt
study software.
Contiguously nested deletion ofthe survivin promoter
luciferase construct
Contiguous deletion of the region from 1430 to 649bp in
pLuc-1430c was carried out using the Erase-a-Base System
(Promega, Madison, WI, USA). Brieﬂy, pLuc-1430c (100–
150mg/ml) was entirely digested with Sal I, followed by
ﬁlling-in with Klenow DNA polymerase (Promega) in the
presence of a-phosphorothioate dNTP and 1mM DTT.
After heat inactivation of the enzyme, the end-blocked
DNA was phenol extracted, ethanol precipitated and
digested with BamH I, followed by a second phenol
extraction and quantiﬁcation. Five microgram of the
digested DNA were incubated at 258Ci n6 0 ml Exo III
digestion buﬀer containing 66mM Tris/HCl (pH 8.0),
0.66mM MgCl2 and 400 units of exonuclease III. Aliquots
(2.5ml) from the above solution were mixed with the S1
digestion buﬀer (7.5ml) containing 40mM potassium
acetate (pH 4.6), 340mM NaCl, 1.35mM ZnSO4, 7%
glycerol and S1 nuclease (300 units/ml) every 15–30s
intervals per time point. The aliquot mixtures from each
time point were incubated at 228C for 30min, stopped
with 1ml of 0.3M Tris-base and 0.05M EDTA and heat
inactivated for 10min at 708C. Contiguous deleted DNA
samples from each time point were blunted with 100–150
units of Klenow/ml for 10min at 378C, re-ligated in
50mM Tris/HCl (pH 7.6), 10mM MgCl2, 1mM ATP, 5%
poly (ethylene glycol), 1mM DTT and 5 units of T4 ligase/
ml at 168C overnight, and transformed into competent
Escherichia coli by electroporation. The clones carrying
progressive deletions from the 50-end were identiﬁed by
PCR ampliﬁcations of 10–20 colonies from each time
point. The exact deletion sites in each clone containing the
expected size were determined by sequencing.
Transfectionand luciferase reporter assay
HeLa cells were seeded in 24-well plates (5 10
4 per well)
and grown at  50–60% conﬂuence for transfection. Each
of the relevant survivin promoter-luciferase constructs
generated previously (11) or in this study was cotrans-
fected with pRL-TK (TK promoter-Renilla-luciferase
construct, internal control) into cells as follows: Brieﬂy,
490ng of a pLuc-survivin construct and 10ng of pRL-TK
in 50ml serum-free DMEM was mixed in a 1.5ml tube
containing 50ml serum-free DMEM and 0.75ml
Lipofectamine
TM 2000. After incubation at room tem-
perature for 20–25min, the DNA/Lipofectamine 2000
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which already contained 400ml DMEM complete growth
medium. The DNA/Lipofectamine 2000 mixture was
replaced by new complete growth medium after incuba-
tion for 6h (replacing medium is not necessary but will
decrease toxicity to transfected cells). Cells were treated
with Hoechst33342 24h after transfection. Cells were
processed for luciferase assays 8–24h after drug treatment.
For the luciferase assay, a Dual-Luciferase Reporter
Assay System (Promega) was used. The transfected cells
in 24-well plates were washed with PBS and lysed with
200ml1 passive lysis buﬀer on a shaker for up to 1h at
48C. Twenty microliter cell lysate per well was used to
measure the Fireﬂy and Renilla luciferase activity in a
Luminometer by subsequently adding 20ml luciferase
assay reagent and 20ml Stop-Glo reagent. Data were
normalized to Renilla luciferase activity (internal control)
as arbitrary units and plotted as a histogram from three
independent experiments. For U937 cells, transfection of
survivin promoter constructs was performed using Fugene
HD Reagents (Roche). Two microgram DNA in 100ml
Opti-1 medium were mixed with 12ml Fugene HD
Reagent for 30min at 258C. The DNA–Fugene HD
complex was then added into each well of a 6-well plate
containing 2 million freshly seeded cells. We replaced
media with or without drugs 6h after transfection.
Luciferase activity was measured 36h after drug
treatment.
MTT(3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium
bromide, atetrazolium salt)assayfor cell growth
HeLa cells were seeded in 96-well plates and grown to
 40% of conﬂuence. Cells were then treated with and
without Hoechst33342at various concentrations for 48
and 72h. Cell viability was then determined using MTT
assay as previously described (12,13). Cell absorbance in
each well was determined at 570nm with an Ultra
Microplate Reader (Bio-Tek Instruments). Results are
reported as the mean SD derived from 5–10 replicates at
each time point.
Invivo footprinting
The ligation-mediated polymerase chain reaction (LM-
PCR) was used for the in vivo footprinting experiment.
LM-PCR was carried out as described elsewhere, with a
number of modiﬁcations (8). Brieﬂy, after cells were
permeabilized with DMS and washed with PBS, they were
treated with or without Hoechst33342 and were then lysed
with lysis solution. Resultant lysates were incubated at
378C for 3–16h, and DNA was extracted with phenol/
chloroform/isoamyl alcohol. The genomic DNA in the
supernatant was precipitated with isopropanol and
ethanol sequentially. The resulted DNA was re-dissolved
and adjusted to a concentration of 0.5–2mg/ml. DNA
isolated from cells without Hoechst33342 treatment were
treated with DMS and quenched with DMS stop solution.
DNA derived from cells treated with Hoechst33342 was
also mixed with DMS stop solution and was then
precipitated with ethanol. The above wet DNA was
dissolved and treated in 1M piperidine and was then
precipitated with ethanol and isopropanol sequentially.
The resultant puriﬁed DNA was resuspended in dH2O,
dried in a SpeedVac and re-dissolved in TE to a
concentration of 0.4–0.6mg/ml for LM-PCR. Two linker
primers (20mM each), LM25 (GCGGTGACCCGGG
AGATCTGAATTC) and LM11 (GAATTCAGATC),
were annealed for LM-PCR. Three microgram of DNA
template per reaction and Vent DNA polymerase were
used for the ﬁrst strand synthesis with atFP1 or atFPr1
(refer to Figure 3 for sequence information), followed by
ligation of the annealing linker primer to the ﬁrst strand
DNA at 168C overnight using T4 DNA ligase. Ten
microgram yeast tRNA was added to the ligated DNA in
each reaction, and the DNA was precipitated with
ethanol. The resultant DNA was used as templates for
PCR using LM25 and atFP2 or atFPr2 (refer to Figure 3)
with Vent DNA polymerase for 21 PCR cycles, followed
by 2 additional PCR cycles after adding g-
32P-ATP
labeled atFP3 or atFPr3. The DNA in each reaction was
extracted by phenol:chloroform:isoamyl alcohol, and the
supernatant was evenly divided into three tubes. The
DNA in each tube was precipitated with ethanol and dried
by allowing evaporation in air. Each of the resultant
samples was resuspended in 4–8ml loading buﬀers and
denatured at 908C for 3–4min. Two to four microliter for
each sample was run on a 6% PAGE gel along with
32P-
labeled fX174 DNA/Hinf I markers.
Isolation of cell nuclear extracts
The isolation of cell nuclear extracts was described in
detail in our recent publication (8). Brieﬂy, HeLa or U937
cells were scraped into ice-cold PBS and collected by
centrifugation. Cell pellets were then gently resuspended
with 3 cpv (cells pellet volume) of the ice-cold buﬀer A,
without TritonX-100, to wash the cells. Cells were then
pelleted gently and resuspended well in 3 cpv of ice-cold
buﬀer A with 0.1% TritonX-100 (w/v). The resuspended
cells were allowed to swell for 12–15min on ice. Cell nuclei
were then collected by centrifugation (3440g) for 15min at
28C and resuspended in 1 pnv (packed nuclei volume) of
ice-cold buﬀer C. The cell suspension was incubated on ice
( 28C) for 30min with continuous mixing. The cell
nuclear extracts (supernatant) were collected by centrifu-
gation at 25000g for 30min at 28C. The nuclear extracts
were frozen in liquid nitrogen in aliquots (50–100ml/each
1.5ml tube) and stored at  808C for gel shift experiments.
Electrophoretic gel mobility shift assay(EMSA)
The EMSA protocol used in this study was described in
detail in our recent publication (8). Brieﬂy, DNA
oligonucleotides (H369W, 50ACA CAC TGA TTT TTT
TTT TAA TAG GCT G30) were labeled at the 50-end with
[g-32P]ATP and used as probes. Nuclear extracts
(8–15mg) were pre-incubated in the binding buﬀer for
20min at 258C in a volume of 19ml with and without
unlabeled oligonucleotide competitors in the presence and
absence of Hoechst33342, or in the presence and absence
of anti-Gﬁ-1 antibody (EMSA supershift assay). After
addition of 1ml labeled DNA (1–2 10
5c.p.m.), the
mixture was incubated for an additional 20min at 258C.
2392 Nucleic Acids Research, 2007, Vol. 35, No. 7Each reaction mixture was then run on a 4% non-
denaturing polyacrylamide gel and electrophoresed at
200V in 1 TBE buﬀer at 258C for 1–2h. To determine
the direct interaction of the 28-bp H369W DNA element
with Hoechst33342, the reaction was run on a 12% instead
of a 4% non-denaturing polyacrylamide gel. Gels were
peeled oﬀ with Waterman paper and covered by Saran
wrap, followed by autoradiography to visualize the
protein–DNA interaction complexes. The DNA sequences
for Sp-1 and Gﬁ-1 used as cold DNA competitors in this
study are 50- ATT CGA TCG GGG CGG GGC GAG C-30
for Sp-1, and 50- GAG TCC TAA ATC ACT GCA CCT
GA-30 for Gﬁ-1, respectively.
Transfection ofsurvivin-targeting expression vectors and
cell deathassay
The expression vectors for survivin dominant-negative
mutant (C84A) (14) and survivin small hairpin RNA
(shRNA) (pG-shRNA1L) (15) were characterized pre-
viously. HeLa cells were seeded in 12-well plates (1 10
5
per well) for ﬂuorescence microscopy studies. Cells at
 40–50% conﬂuence were transfected with either
pEGFPc1 (control vector, Clontech) or with the expres-
sion vectors survivin C84A (pG-C84A) or survivin
shRNA (pG-shRNA1L) (15). Brieﬂy, 1mg vector DNA
in 100ml serum-free DMEM was mixed with 1.8ml
Lipofectamine
TM 2000 in 100ml serum-free DMEM in a
1.5ml tube for each well of 12-well plates. The DNA/
Lipofectamine
TM 2000 mixture was added to each well
containing 600ml complete cell growth medium after
incubation at room temperature for 20–40min. The
DNA/Lipofectamine
TM 2000 complex was replaced by
complete growth medium after incubation for 6h (repla-
cement of medium, while not imperative, decreases non-
speciﬁc toxicity). Twenty-four hours after transfection,
cells were treated with Hoechst33342 for 16h. Cells were
ﬁxed with 4% paraformaldehyde containing 0.25%
TritonX-100 for 10min, mounted using mounting solution
containing 0.05% DAPI and sealed with round cover
glasses.
Statistical analysis
A two-group t-test was performed for a pairwise
comparison of each experimental group with the control
assuming equal variance. When necessary, a square-root
transformation was applied to standardize the residuals to
be approximately normal. The signiﬁcance (P-value) was
set at the nominal level of less than or equal to 0.05.
RESULTS
Hoechst33342 upregulates theexpression ofsurvivin
protein, mRNA and promoter activity
We previously reported that hedamycin, a GC-rich
sequence-selective DNA-binding antitumor agent, down-
regulates survivin expression and its promoter activity in
cancer cells (8). In contrast with this ﬁnding, we show here
that treatment of HeLa and HCT116 cancer cells with
Hoechst33342, an AT-rich sequence-selective DNA-
binding ligand, increased survivin protein level (Figure
1A) and its mRNA level (Figure 1B) as determined by
western and northern blots, respectively. We further
conﬁrmed these data by real-time QPCR in HeLa cells
(Figure 1C) as well as in U937 cells (Figure 1D). To
determine whether survivin mRNA increase reﬂects
survivin transcriptional regulation, we subsequently per-
formed survivin promoter-luciferase reporter assay, which
indicated that Hoechst33342 ligand indeed increases
survivin promoter activity (Figure 1E). These results are
not only consistent with the diﬀerential sensitivity of cell
death to diﬀerent DNA-binding ligands (Figure 2), but
also suggest a potential mechanism underlying cancer cell
resistance following exposure to Hoechst33342, which
correlates with the transcriptional upregulation of the
survivin gene by Hoechst33342.
A117-bp DNA element between pLuc-956 and pLuc-839
plays amajorrole inHoechst33342-induced survivin
promoter activity
To investigate the mechanism by which Hoechst33342
upregulates survivin expression and promoter activity
(Figure 1), a series of truncated survivin promoter-
luciferase constructs previously characterized (11) were
transfected into HeLa cells, and treated with or without
Hoechst33342 for 24h, followed by a quantiﬁcation of
luciferase activity. The experiment revealed that a 718-bp
DNA fragment between pLuc-1430 and pLuc-649 con-
structs appears to mediate the eﬀect of Hoechst33342 on
the induction of survivin promoter activity (Figure 3A).
Next, we performed a detailed contiguous deletion from
1430 to 649 in the survivin promoter-luciferase construct.
The resultant new survivin promoter-luciferase constructs
were transfected into HeLa cells, followed by
Hoechst33342 treatment and luciferase activity assays.
The experiment further revealed that the 117-bp DNA
element between pLuc-956 and pLuc-839 mediates a
major eﬀect of Hoechst33342 on the upregulation of
survivin promoter activity (Figure 3B).
Invivo footprinting revealedan alteration ofDNA–protein
interactions inan AT-rich DNA element after
Heochst33342 treatment
Next, we employed the ligation-mediated (LM)-PCR in
vivo footprinting technique to determine whether
Hoechst33342 could alter the DNA–protein interactions
in the functionally identiﬁed 117-bp DNA element (Figure
4A). The in vivo footprinting analyses indicated that
Hoechst33342 treatment increases the sensitivity of cells to
DMS-mediated piperidine digestion at the AT-rich DNA
element within the 117-bp DNA region (compare lane 2
with lane 1, Figure 4B). This result is consistent with the
fact that there is only one AT-rich DNA element in the
functionally identiﬁed 117-bp DNA element (Figure 4A).
Hoechst33342 binds tothe 28-bpAT-rich DNA element
andalters its DNA–protein interactions
Next, we tested whether Hoechst33342 indeed binds to the
28-bp AT-rich DNA element (designated as H369W)
using EMSA experiments. Consistent with the fact that
Nucleic Acids Research, 2007, Vol. 35, No. 7 2393Hoechst33342 has a net positive charge in aqueous
solution together with a unique pattern of H-bond
acceptors/donors presented by a concave surface (Figure
5A), EMSA experiments revealed that Hoechst33342
strongly binds to H369W (Figure 5B). To test whether
any transcription repressor protein binds to this 28-bp
AT-rich DNA element, with which Hoechst33342 treat-
ment might interfere, we searched for potential transcrip-
tion factor-binding sites in H369W and found that the
consensus DNA-binding site for the transcription repres-
sor protein Gﬁ-1 is highly homologous to a part of the 28-
bp AT-rich DNA element (Figure 6A). To test whether the
Gﬁ-1 protein or Gﬁ1-like proteins may bind to the
H369W DNA element, a competitive EMSA was
performed using HeLa cell nuclear extracts. This experi-
ment showed that cold canonical Gﬁ-1 oligonucleotides
competed with the DNA–protein complex, while the cold
canonical Sp-1 oligonucleotides were unable to compete
with the DNA–protein complex (not shown). It was
previously reported that U937 cells highly express Gﬁ-1
proteins (16). Therefore, nuclear extracts isolated from
U937 cells were also used in EMSA. The results from this
cell type indicated that both the cold H369W DNA
element and the canonical DNA motif for Gﬁ-1 binding
could eﬀectively compete with the DNA–protein complex,
while the non-speciﬁc (scramble) DNA could not do so
(Figure 6B). Further, consistent with the data from in vivo
footprinting showing that Hoechst33342 treatment sensi-
tizes this DNA element to DMS-mediated piperidine
digestion at the H369W AT-rich DNA element (Figure 4),
Hoechst33342 was able to compete with the H369W–
protein complex, while DAPI and Distamycin failed to do
so under these conditions (Figure 6B), even though both
were shown to bind to AT-rich DNA sequences (17,18).
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Figure 1. Hoechst33342 upregulates survivin expression and its promoter activity (A) Hoechst33342 induces the expression of survivin protein. HeLa
and HCT116 cells were treated as indicated for 20h. Survivin expression was determined by western blots. b-actin expression was used as an internal
control for total protein loading. (B) Hoechst33342 induces survivin mRNA expression. HeLa cells were treated as indicated. Survivin mRNA
expression was determined by northern blots. GAPDH mRNA expression was used as an internal control for total RNA loading. (C) and (D)
Quantitative real-time PCR. The induction of survivin mRNA expression by Hoechst33342 in HeLa cells (C) and in U937 cells (D). Real-time QPCR
was performed as described in the Materials and methods section. Each bar is the mean SD derived from three independent assays.
(E) Hoechst33342 upregulates survivin promoter activity. HeLa cells were transfected with the survivin promoter-luciferase construct, pLuc-6270
together with the internal control vector, pRL-TK. Cells were then treated with Hoechst33342 as indicated for 24h. Luciferase activities were
measured using the Dual Luciferase Reporter System (Promega). Data were derived from the experiment in triplicate after normalization to the
Renilla luciferase activities (internal control) and are shown as a histogram. Each bar is the mean SD (standard deviation).
2394 Nucleic Acids Research, 2007, Vol. 35, No. 7These observations strongly point to the speciﬁcity of the
interaction between Hoechst33342 and H369W. The
presence of Gﬁ-1 proteins in the DNA–protein complex
was further conﬁrmed by gel supershift assay experiments
in which a supershift band appeared in the presence of
Gﬁ-1 antibody (Figure 6C). Thus, the protein binding to
H369W probes shown in Figure 6B at least partially
represents the Gﬁ-1 suppressor’s binding to this DNA
motif. Using U937 cells, we further demonstrated that
Hoechst33342 could eﬀectively upregulate survivin pro-
moter activity only from the pLuc-957 construct contain-
ing the H369W motif, while it failed to do so from the
pLuc-839 construct lacking the H369W motif (Figure 6D).
Moreover, consistent with the fact that Gﬁ-1 expression is
much higher in U937 cells than that in HeLa cells,
Hoechst33342 showed a stronger upregulation of survivin
promoter activity in U937 cells (Figure 6D) as compared
to HeLa cells (Figure 3B). Additionally, real-time QPCR
(Figure 6E) and western blot analysis (Figure 6F)
indicated that Hoechst33342 is unable to downregulate
Gﬁ-1 mRNA (which actually increases) or protein
expression. Finally, a Bioinformatics search in the whole
human genome revealed that the 28-bp AT-rich motif is
highly conserved in the putative promoter region of the
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Figure 2. Comparison of the cytotoxicity of Hoechst33342 with hedamycin HeLa cells were seeded in 24-well plates and grown to a 50% of
conﬂuence. Cells were then treated with and without various concentration of Hoechst33342 (A) or hedamycin (B) as shown. Cell images were taken
under an inverted phase-contrast microscope with a digital camera at 24 and 48h after treatment. (C) HeLa cell growth inhibition after
Hoechst33342 treatment. Cells were seeded in 96-well plates and grown to  40% of conﬂuence. Cells were then treated with and without
Hoechst33342, as shown. Cell viability was determined by MTT assay. Absorbance at 570nm for the control (no Hoechst33342) is set as 1 and
results are reported in a histogram (the mean SD from 5–10 measurements for each point).
Nucleic Acids Research, 2007, Vol. 35, No. 7 2395cell division cycle associated 2 gene and a hypothetical
gene. Further, this DNA motif is also conserved ( 20bp)
in the ﬁrst intron of other human genes (see Discussion
section for more detail). Together, these observations
imply that the identiﬁed DNA element may represent a
functional motif for gene transcription control in general.
Upregulation ofsurvivin by Hoechst33342is a
drug-resistant factor
To investigate whether upregulation of survivin by
Hoechst33342 is involved in Hoechst33342 resistance
and debilitates Hoechst33342’s eﬀects on cell-death
induction, we took advantage of the previously character-
ized survivin antagonists, C84A dominant-negative
mutant (14) or survivin shRNA (15). We transfected
these expression vectors into HeLa cells to counteract the
induction of survivin expression by Hoechst33342. Cell
death (condensed small nuclei) in the transfected cells
(green) was then monitored under a ﬂuorescence micro-
scope. These experiments indicated that, in comparison
with the empty vector-transfected control cells, targeting
survivin signiﬁcantly increased the percentage of cells with
condensed small nuclei (an apoptotic hallmark) after
Hoechst33342 treatment (Figure 7A and B). These
observations suggest that induction of survivin expression
by Hoechst33342 plays a role in Hoechst33342-resistance
and, moreover, counteracting the Hoechst33342-mediated
induction of survivin with survivin antagonists, sensitizes
cancer cells to ligand-induced death. Consistent with this
conclusion, pretreatment of HeLa cells with a low
concentration (suﬃcient to induce survivin expression
but not to cause cell death, compare Figure 8A-b and
Figure 8A-c) of Hoechst33342 in order to counteract the
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Figure 3. Mapping the survivin promoter region that mediates Hoechst33342’s eﬀects on the induction of survivin promoter activity. (A) The 781-bp
DNA region between pLuc-1430 and pLuc-649 was identiﬁed to mediate the upregulation of survivin promoter activity by Hoechst33342. HeLa cells
were transfected with various survivin promoter-luciferase constructs as shown and treated with or without Hoechst33342 (5mM) 24h after
transfection. Cells were lysed and luciferase activities were determined 24h after treatment. (B) Nested deletion of the 781-bp DNA region between
pLuc-1430 and pLuc-649 identiﬁed a 117-bp DNA region mediating a major eﬀect of Hoechst33342. Transfection, drug treatment and luciferase
assay are as in (A). In both (A) and (B), luciferase activities were normalized to Renilla luciferase internal controls as arbitrary units and are shown
as a histogram. Each bar is the mean SD from the experiment in triplicate.
2396 Nucleic Acids Research, 2007, Vol. 35, No. 7downregulation of survivin by hedamycin, suppressed
hedamycin-induced cell death (Figure 8A and B).
Furthermore, the survivin promoter-luciferase activity
assay indicated that pretreatment of cells with
Hoechst33342 has a superior ability to inhibit the down-
regulation of survivin promoter activity, achieved with
hedamycin, as compared to concurrent treatment of cells
with these two drugs (Figure 8C, compare lanes 2, 3 with
lanes 5, 6). Conversely, it appears that hedamycin can also
attenuate the Hoechst33342-mediated induction of survi-
vin promoter activity (Figure 8C, compare lanes 2, 3 with
lanes 7, 8).
DISCUSSION
It is known that expression of survivin in cancer is
associated with cancer progression and drug resistance (6).
Inhibition of survivin expression or survivin function
appears to be important for cancer treatment (19).
Current studies indicate that various transcriptional
factors and/or signaling molecules appear to transcrip-
tionally and post-transcriptionally control the expression
of survivin (20). Importantly, growing evidence reveals
that the transcriptional and/or post-transcriptional reg-
ulation of survivin expression appears to be diﬀerent in
cancer cells versus normal cells (20,21). This important
insight could provide exciting opportunities for cancer
therapy without or with low toxicity to normal cells and
tissues. Additionally, given the multiple subcellular
localizations and multiple functions of survivin (4,6),
both understanding survivin transcriptional control at the
molecular level and ﬁnding an easy way to modulate
survivin transcription, has signiﬁcant translational impli-
cations for the development of novel approaches for
cancer treatment. We recently reported that a GC-rich
sequence-selective DNA-binding antitumor agent,
Figure 5. Hoechst33342 directly binds to the 28-bp AT-rich DNA
element. (A) Structure of the Hoechst33342 ligand. (B) EMSA shows
the direct interaction of the 28-bp AT-rich DNA element (H369W) with
Hoechst33342. The 28-bp H369W AT-rich DNA probe in the absence
(lane 1) or presence (lanes 2–4, 1, 10 and 100nM) of Hoechst33342 was
run on a 12% non-denatured PAGE gel.
Figure 4. In vivo footprinting identiﬁed the alteration of DNA–protein interactions in an AT-rich DNA element in the functionally identiﬁed 117-bp
fragment after Hoechst33342 treatment. (A) DNA sequences from  779 to  1108 containing the functionally identiﬁed 117-bp DNA fragment. The
primers used for LM-PCR and the 28-bp AT-rich DNA element in bold are indicated. (B) Hoechst33342 protected an AT-rich DNA element from in
vivo DMS-mediated piperidine digestion. HeLa cells were treated with (lane 2) or without (lane 1) 50nM Hoechst33342 for 16h and then processed
DMS-mediated piperidine digestions and LM-PCR. Positions of the AT-rich DNA element and the protected band in lane 1 from forward (atFP3)
and reverse (atFPr3) directed LM-PCR are indicated.
Nucleic Acids Research, 2007, Vol. 35, No. 7 2397hedamycin, transcriptionally downregulates survivin
expression through abrogation of Sp-1 or Sp1-like
proteins, which bind to a 21-bp GC-rich motif in the
survivin core promoter region and, that downregulation of
survivin transcription by hedamycin, is associated with the
enhancement of hedamycin’s eﬀectiveness to induce
cancer cell death (8). In the current study, we have
characterized the eﬀect of Hoechst33342, an AT-rich
sequence-selective DNA-binding ligand, on the regulation
of survivin gene transcription. We found that in contrast
to the inhibition of survivin transcription by hedamycin,
Hoechst33342 increases survivin protein, mRNA and
promoter activity (Figure 1). Importantly, this opposite
or inverse modulation of survivin promoter activity by
hedamycin compared to Hoechst33342 is achieved using
an equi-cytotoxic concentration of the ligands, respec-
tively. An equi-toxic concentration allowed us to make the
unambiguous conclusion that the opposite eﬀect on
survivin expression is attributable to the opposite actions
of the hedamycin and Hoechst33342. Speciﬁcally,
Hoechst33342 upregulates survivin promoter activity at
concentrations of 5, 10 and 20mM (Figure 1E), while
hedamycin in the equi-cytotoxic range of concentrations
(Figure 2) of 10, 25 and 50nM strikingly downregulates
survivin promoter activity (8). Using survivin promoter-
luciferase reporter assay, in vivo footprinting, and EMSA
experiments, we identiﬁed a 28-bp AT-rich DNA element
(H369W) in which Hoechst33342 interacted with and
abrogated DNA–protein interactions at this locus
(Figures 3–6). Our in vivo footprinting experiments
Figure 6. Hoechst33342 disrupts the interaction of Gﬁ-1 or Gﬁ-1 like proteins with the 28-bp AT-rich DNA element (H369W). (A) H369W harbors a
Gﬁ-1-like DNA-binding site. (B) Hoechst33342 abrogates the interaction of Gﬁ-1 or Gﬁ-1 like proteins with the H369W DNA element. DNA–
protein-binding reactions were run on a 4% non-denatured PAGE gel. Combinations of the H369W DNA element probe with nuclear extracts,
Hoechst33342, speciﬁc DNA competitors (cold H369W or cold Gﬁ-1) and non-speciﬁc competitors (scramble DNA oligonucleotides) as well as two
other ligands (DAPI and Distamycin) are indicated. (C) Gﬁ-1 antibodies supershift the upper H369W–protein complex. The experiment condition is
as in (B). As indicated, in the presence of anti-Gﬁ-1 antibody, the upper DNA–protein complex was supershifted (see Discussion section for the lower
band). (D) Hoechst33342 strongly induces survivin promoter activity in pLuc-957 possessing the 28-bp DNA element, while it has no signiﬁcant eﬀect
on survivin promoter activity in the pLuc-839 construct without the 28-bp DNA element. The histogram data were derived from three independent
experiments. Each bar is the mean SD. (E) and (F) Hoechst33342 induces Gﬁ-1 mRNA expression (E), while it has no signiﬁcant eﬀect on Gﬁ-1
protein expression (F). Data in (E) represents real-time QPCR from three independent testing. Each bar is the mean SD. Data in (F) is western blot
analysis. Actin is the internal protein loading control.
2398 Nucleic Acids Research, 2007, Vol. 35, No. 7revealed that Hoechst33342 treatment sensitizes the
H369W AT-rich DNA element to DMS-mediated
piperidine digestion, suggesting the abrogation of the
DNA–protein interaction within the region (Figure 4).
This in vivo data were further conﬁrmed by the in vitro
DNA–protein interaction experiments (Figures 5–6).
Using U937 cell nuclear extracts, we demonstrated that
the cold canonical Gﬁ-1 binding DNA motif could
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Figure 7. Targeting survivin by survivin dominant-negative mutant (C84A) or survivin shRNA sensitizes cells to Hoechst33342-induced cell death.
(A) HeLa cells at 40–50% conﬂuence were transfected with control vector (pEGFPc1) or with expression vectors for survivin C84A or survivin
shRNA as indicated. Twenty-four hours after transfection, cells were treated with or without Hoechst33342 (500nM) for 16h. Cells were then ﬁxed
and stained with DAPI. Apoptotic cells (condensed small nuclei) in the transfected (green) cells were morphologically evaluated. Examples of non-
apoptotic cells (upper panel) and apoptotic cells (middle and lower panels) with EGFP positive (green) are arrowed. (B) The histogram shows the
percentage of cell death in each condition derived from the calculation of dead cells among total green cells from four microscopic ﬁelds. Each bar is
the mean SD from three independent calculations.
Nucleic Acids Research, 2007, Vol. 35, No. 7 2399compete with the H369W DNA–protein complex while
the scramble DNA failed to do so (Figure 6B).
Consistently, the canonical Gﬁ-1 transcriptional repres-
sor-binding site is highly conserved in the 28-bp AT-rich
DNA element (H369W, Figure 6A). This may explain the
high eﬃciency of cold canonical Gﬁ-1 binding DNA
oligonucleotides to compete with the H369W–protein
complexes in the EMSA experiment (Figure 6B). It is
likely that Gﬁ-1 or Gﬁ1-like proteins bind to the H369W
AT-rich DNA element before Hoechst33342 treatment.
This was further conﬁrmed by gel supershift assay experi-
ments (Figure 6C). However, we notice that while cold
canonical Gﬁ-1 or H369W oligonucleotides eﬀectively
competed with the DNA–protein complexes (Figure 6B),
anti-Gﬁ-1 antibody was only able to supershift the upper
band but not the lower band (Figure 6C). A couple of
possibilities may account for this inconsistency. First, the
anti-Gﬁ-1 antibody we used in this study may not be able
to recognize Gﬁ1-like protein. Second, the proteins in the
lower band may be irrelevant to Gﬁ-1 or Gﬁ1-like
proteins. In any case, the lower DNA–protein complex
band shown in Figure 6C is unlikely a non-speciﬁc DNA–
protein complex since cold non-speciﬁc/scramble DNA
could not compete with this DNA–protein complex but
both cold canonical Gﬁ-1 and H369W oligonucleotides
could do so (Figure 6B). Nevertheless, the involvement of
the identiﬁed 28-bp AT-rich DNA element (H369W) in
survivin gene regulation was further supported by the fact
that Hoechst33342 could upregulate survivin promoter
activity from the pLuc-957 survivin promoter-luciferase
construct containing the H369W motif but not from the
pLuc-839 construct lacking H369W motif (Figure 6D).
The possibility that Gﬁ-1 may suppress survivin gene
transcription is suggested in the literature as well. For
example, it has been demonstrated that Gﬁ-1 restricts
hematopoietic stem cell proliferation (22–24) and consis-
tently, survivin is known to be involved in the promotion
of cell proliferation (6). It is possible that Gﬁ-1 inhibits cell
proliferation through the suppression of survivin gene
transcription. Thus, one explanation for the
Hoechst33342-mediated increase survivin promoter activ-
ity is that the interaction of Hoechst33342 with the
H369W AT-rich DNA element results in the dissociation
of Gﬁ-1 or Gﬁ-1-like proteins from H369W, enhancing
the permissiveness for survivin transcription. Here, we
should point out that the characterized 28-bp AT-rich
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Figure 8. A low concentration of Hoechst33342 protects cells from death induced by hedamycin. (A) HeLa cells were equally seeded in 24-well plates.
Cells grown to 70–80% conﬂuence were treated without (a) and with Hoechst33342 (b), hedamycin (c) or Hoechst33342/hedamycin combination (d)
as shown. Note: Hoechst33342 was added 2h before adding hedamycin. Images were taken 36h after adding hedamycin. (B) Trypan blue exclusion
assays were used to count the number of alive cells after treatment in (A). Data presented in a histogram are the mean SD derived from three
independent well countings. (C) Modulation of survivin promoter activity by hedamycin (Hed) and Hoechst33342 (Hoe) alone and in combination.
HeLa cells were transfected with survivin promoter-luciferase construct pLuc-1430. Cells were treated with Hed (0.5 and 1nM) and Hoe (250nM)
alone or in combination as shown. Luciferase activity was measured 36h after drug treatment. Each bar in the histogram is the mean SD derived
from three independent testings. Seq, sequentially (Hed was added to cells after Hoe treatment for 2h); con, concurrently.
2400 Nucleic Acids Research, 2007, Vol. 35, No. 7DNA elements may not be the only DNA element
involved in Hoechst33342’s eﬀects on the upregulation
of survivin promoter activity, although this DNA element
appears to play a major role. For example, based on
the functional data shown in Figure 3B, the
DNA fragment between pLuc-1332 and pLuc-1242
appears to be involved in the ligand’s eﬀect on survivin
promoter activity as well. Consistent with this notion,
there is an AT-rich DNA sequence within this region
(
 1303TACTAAAAATACAAAAATTA
 1284).
It was previously reported that Hoechst33342 could
aﬀect the initiation of RNA polymerase II activity by
altering the formation of the TATA-box binding protein
(TBP) within the TATA box motif from the adenovirus-
major-late-promoter in EMSA experiments (25). The
presence of Hoechst33342 (26.7mM) decreased the
amount of the control complex and increased the presence
of lower molecular weight species, suggesting the degrada-
tion of nuclear TBP and/or the release of other transcrip-
tion factors from the complex (25). However, the above
ﬁnding is unlikely to explain Hoechst33342’s eﬀects on
survivin transcription. This is because the survivin
promoter is a GC-rich promoter without a TATA-box
motif. While there is no TATA-box motif within the
survivin core promoter, several AT-rich elements exist
upstream of the GC-rich core promoter region of survivin.
One of these AT-rich elements is the 28-bp cis-acting motif
identiﬁed in this report (designated as H369W).
Interestingly, in addition to the previous ﬁnding that
Hoechst33342 interferes with the TBP/TATA-box motif
complex formation to suppress gene transcription (25),
our experiments suggest an alternative ligand–DNA–
protein interaction model in which Hoechst33342 actually
displaces Gﬁ-1 or Gﬁ-1-like transcription suppressor
proteins from the 28-bp AT-rich DNA element.
However, we should point out that while our study
identiﬁed a role of the 28-bp AT-rich DNA element in
survivin gene transcription, this study has not excluded
potential roles of other AT-rich sequences in survivin
transcriptional controls. Furthermore, in the EMSA
experiment both distamycin and DAPI at their equal
concentrations to that of Hoechst33342 (10–20nM) were
unable to compete with the DNA–protein complexes
(Figure 6B). This does not exclude the possibility that at
higher concentrations, distamycin or DAPI would still be
unable to do so. Our experiments indicate that distamycin,
at very high concentrations (10–400mM), enhances
survivin promoter activity (not shown), with the highest
increase in survivin promoter activity at 400mM. But this
is in striking contrast to the dynamic pattern for
Hoechst33342 in this study (Figure 1E). Additionally,
DAPI at the tested concentrations of 2, 10, 20, 100 and
1000nM showed no eﬀect on survivin promoter activity.
These observations argue for the diﬀerential speciﬁcity for
these ligand actions.
Hoechst33342 has been reported to be a cell death-
inducing agent (26). However, our experiments show that,
compared to hedamycin, Hoechast33342 appears to be
much less potent. Our data shown in Figure 2 indicate that
hedamycin is at least over a hundred times more eﬀective
than Hoechst33342at inducing cancer cell death. This is
consistent with our observation that hedamycin down-
regulates but Hoechst33342 upregulates the expression of
survivin. To determine whether upregulation of survivin
by Hoechst33342 indeed contributes to Hoechst33342
resistance, we took advantage of our previously char-
acterized survivin antagonists (14,15) to counter the
induction of survivin by Hoechst33342 during treatment
(Figure 7). Consistent with our previous ﬁnding that
taxol/paclitaxel upregulates survivin, which increases cell
viability and drug resistance (9), forced expression of
survivin antagonists sensitized cells to death induced by
Hoechst33342 (Figure 7). Given that survivin requires its
Baculovirus IAP Repeat (BIR) domain to inhibit apop-
tosis and promote cell division, the sensitization of cells to
drug-induced death could be either due to the induction of
apoptosis or through forcing cells into a state (such as
growth arrest), in which cells are easily attacked by
antitumor agents. Nevertheless, using a low concentration
of Hoechst33342 that does not induce cell death but
substantially upregulates the expression of survivin, we
demonstrated that Hoechst33342at this concentration
alleviates hedamycin-induced cell death, apparently a
consequence of the induction of survivin expression by
Hoechst33342. Together, these observations suggest that
upregulation of the drug-resistant factor survivin by
Hoechst33342 diminishes the eﬀectiveness of the
Hoechst33342 ligand to induce cell death.
Finally, it would be interesting to know if the identiﬁed
28-bp DNA element has general roles in transcriptional
control of other genes. A comprehensive sequence search
of the whole human genome indicated that the 28-bp AT-
rich DNA element is highly conserved ( 20bp of identify)
in the putative promoter region of the CDCA2 (cell
division cycle associated 2) gene as well as in the ﬁrst
intron of 17 additional human genes. Examples of these
genes include the syndecan-binding protein (Syntenin/
SDCBP), which was found to promote cell migration in
metastatic breast and gastric cancer cells (27), and the
target of the myb1-like2 (TOM1L2) gene. Together, these
ﬁndings argue that the identiﬁed AT-rich DNA element
may play an important role in the regulation of gene
transcription in general.
In conclusion, in this report, we have exposed a novel
molecular mechanism by which Hoechst33342 upregulates
survivin transcription. Our ﬁnding may provide new
opportunities for the development of novel approaches
and/or new ligands to modulate the expression of the
survivin gene for cancer treatment.
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